RxDoctor Payments Data

Carrie Steichen, DO

Interventional Pain Medicine · Pensacola, FLNPI 1710004544

Payments from drug & device makers

$6,892in general payments, 2019–2025

Across 121 payments — averaging $56.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$888
  • Abbott$571
  • AbbVie$326
  • Nevro Corp.$214
  • MML US, Inc.$173
  • plus $834 from 19 others

What the payments were for

  • Speaking & faculty fees$1,40020%
  • Food & beverage$5,45779%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,892 in reported general payments places this provider in the 55th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$492,098
Medicare patients
935
Services billed
9,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,362$35,082
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen867$31,783
BotoxOnabotulinumtoxina17$18,795
BelbucaBuprenorphine Hcl22$14,368
Buprenorphine71$14,161
Pregabalin288$6,822
Tramadol Hcl ErTramadol Hcl72$4,107
Morphine Sulfate ErMorphine Sulfate150$2,989
Gabapentin178$2,795
Tramadol Hcl218$2,096
Naloxone Hcl31$1,741
Tizanidine Hcl64$1,412
Diclofenac Sodium33$1,070
Oxycodone Hcl74$1,033
Methadone Hcl68$941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$326$18,79517 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$35$14,68095 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →